Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7090 Monotherapy and Combination Therapy in ER+, HER2- Recurrent/Metastatic Breast Cancer
NCT04572295Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tasurgratinib in breast cancer (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Recommended Dose, Dose-limiting Toxicities and 1 more. Started Oct 2020; status: completed.
02
Drugs
tasurgratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04572295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572295.